Publications in collaboration with researchers from Medical University of Vienna (26)

2024

  1. Molecular states associated with dysfunction and graft loss in heart transplants

    Journal of Heart and Lung Transplantation, Vol. 43, Núm. 3, pp. 508-518

  2. Redefining the molecular rejection states in 3230 heart transplant biopsies: Relationships to parenchymal injury and graft survival

    American Journal of Transplantation, Vol. 24, Núm. 8, pp. 1414-1426

2023

  1. Donor heart selection: Evidence-based guidelines for providers

    Journal of Heart and Lung Transplantation, Vol. 42, Núm. 1, pp. 7-29

  2. SERCA2a Protein Levels Are Unaltered in Human Heart Failure

    Circulation, Vol. 148, Núm. 7, pp. 613-616

  3. Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial

    JAMA Neurology, Vol. 80, Núm. 8, pp. 779-788

  4. Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial

    JACC: Heart Failure, Vol. 11, Núm. 12, pp. 1729-1738

2022

  1. Assessing the Relationship Between Molecular Rejection and Parenchymal Injury in Heart Transplant Biopsies

    Transplantation, Vol. 106, Núm. 11, pp. 2205-2216

  2. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  3. Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies

    European heart journal, Vol. 43, Núm. 23, pp. 2237-2246

  4. Indications, Complications, and Outcomes of Cardiac Surgery After Heart Transplantation: Results From the Cash Study

    Frontiers in Cardiovascular Medicine, Vol. 10

  5. Many heart transplant biopsies currently diagnosed as no rejection have mild molecular antibody-mediated rejection-related changes

    Journal of Heart and Lung Transplantation, Vol. 41, Núm. 3, pp. 334-344

2021

  1. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

    New England Journal of Medicine, Vol. 384, Núm. 2, pp. 105-116

  2. Core outcome measurement instrument selection for physical function in hand osteoarthritis using the OMERACT Filter 2.1 process

    Seminars in Arthritis and Rheumatism, Vol. 51, Núm. 6, pp. 1311-1319

2020

  1. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

    European Journal of Heart Failure, Vol. 22, Núm. 11, pp. 2160-2171

2019

  1. 2018 update of the EULAR recommendations for the management of hand osteoarthritis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 1, pp. 16-24

  2. 2019 EACTS Expert Consensus on long-term mechanical circulatory support

    European Journal of Cardio-thoracic Surgery, Vol. 56, Núm. 2, pp. 230-270

  3. An integrated molecular diagnostic report for heart transplant biopsies using an ensemble of diagnostic algorithms

    Journal of Heart and Lung Transplantation, Vol. 38, Núm. 6, pp. 636-646

2018

  1. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 20, Núm. 11, pp. 1505-1535

  2. Exploring the cardiac response to injury in heart transplant biopsies

    JCI insight, Vol. 3, Núm. 20

  3. The management of antibodies in heart transplantation: An ISHLT consensus document

    Journal of Heart and Lung Transplantation, Vol. 37, Núm. 5, pp. 537-547